Article Information
History
- January 31, 2023.
Article Versions
- Version 1 (May 25, 2022 - 14:01).
- Version 2 (January 25, 2023 - 14:18).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Ferhan Qureshi1,*,#,
- Wayne Hu1,*,
- Louisa Loh1,
- Hemali Patel1,
- Maria DeGuzman1,
- Michael Becich1,†,
- Fatima Rubio da Costa1,†,
- Victor Gehman1,†,
- Fujun Zhang1,†,
- John Foley2 and
- Tanuja Chitnis3
- 1Octave Bioscience, Inc., Menlo Park, CA, USA
- 2Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, UT, USA
- 3Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- ↵#Correspondence
Ferhan Qureshi, 1440 Obrien Drive, Suite B, Menlo Park, CA 94025, USA, Email: fqureshi{at}octavebio.com, Phone: 650-224-3072, Fax: 650-479-8876
↵* These authors contributed equally to this work
Posted January 31, 2023.
Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis
